psalexa
logo

Osteoporosis Drugs Market

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulators, Rank Ligand Inhibitor, Calcitonin and Others)

Published: November 2016
Report Code: LS10177
Available Format:
Pages: 94

Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Research Scope

1.2.1 Global osteoporosis drug market breakdown by drug type

1.2.2 Global osteoporosis drug market breakdown by geography

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.1.1 Causes

3.1.2 Signs and Symptoms

3.1.3 Diagnosis

3.1.4 Prevention and Treatment

3.2 Trends in the Global Osteoporosis Drug Market

3.2.1 Increasing awareness of osteoporosis care

3.3 Factors Driving Growth of the Market and its Impact on Market Forecast

3.3.1 Increasing prevalence of osteoporosis

3.3.2 Rapid urbanization affecting bone health

3.3.3 Increasing prevalence of osteoporosis in post-menopausal women

3.3.4 Increasing healthcare expenditure

3.3.5 Growing geriatric population

3.3.6 Increasing R&D investment in drug discovery and development

3.3.7 Impact analysis of drivers on market forecast

3.4 Factors Hindering Growth of the Market and its Impact on Market Forecast

3.4.1 Side-effects and complications associated with administration of osteoporosis drug

3.4.2 Patent expiration of osteoporosis drug

3.4.3 Limited healthcare reimbursement

3.4.4 Impact analysis of restraints on market forecast

Chapter 4. Drug Approval Process in U.S. and Europe

4.1 Drug approval process in the U.S.

4.2 Drug approval process in the EU

Chapter 5. Global Osteoporosis Drug Market Size and Forecast (2012-2022)

5.1 Global Osteoporosis Drug Market, by Drug Type

5.2 Global Osteoporosis Drug Market, by Region

Chapter 6. Global Osteoporosis Drug Market, by Drug Type

6.1 Bisphosphonates Market

6.1.1 Global bisphosphonates market, by region

6.2 Parathyroid Hormone Therapy Market

6.2.1 Global parathyroid hormone therapy market, by region

6.3 Calcitonin Market

6.3.1 Global calcitonin market, by region

6.4 Selective Estrogen Receptor Modulator (SERM) Market

6.4.1 Global SERM market, by region

6.5 Rank Ligand Inhibitor Market

6.5.1 Global rank ligand inhibitor market, by region

Chapter 7. Global Osteoporosis Drug Market, by Geography

7.1 North America Osteoporosis Drug Market

7.1.1 North America osteoporosis drug market, by drug type

7.1.2 North America osteoporosis drug market, by country

7.2 Europe Osteoporosis Drug Market

7.2.1 Europe osteoporosis drug market, by drug type

7.2.2 Europe osteoporosis drug market, by country

7.3 Asia-Pacific Osteoporosis Drug Market

7.3.1 Asia-Pacific osteoporosis drug market, by drug type

7.3.2 Asia-Pacific osteoporosis drug market, by country

7.4 RoW Osteoporosis Drug Market

7.4.1 RoW osteoporosis drug market, by drug type

Chapter 8. Competitive Analysis

8.1 Porters Five Forces of Competitive Position Analysis

8.1.1 Bargaining power of buyers

8.1.2 Bargaining power of suppliers

8.1.3 Threat of new entrants

8.1.4 Intensity of rivalry

8.1.5 Threat of substitutes

8.2 Competitive Positioning of the Global Osteoporosis Drug Market

8.2.1 Competitive Positioning of Global Osteoporosis Drug Market, by Drug Type

Chapter 9. Company Profiles and Strategic Developments

9.1 Key Company Profiles

9.1.1 Pfizer, Inc.

9.1.1.1 Business overview

9.1.1.2 Product and service offerings

9.1.2 Eli Lily and Company

9.1.2.1 Business overview

9.1.2.2 Product and service offerings

9.1.3 F. Hoffmann La Roche

9.1.3.1 Business overview

9.1.3.2 Product and service offerings

9.1.4 Novartis AG

9.1.4.1 Business overview

9.1.4.2 Product and service offerings

9.1.5 Merck & Co., Inc.

9.1.5.1 Business overview

9.1.5.2 Product and service offerings

9.1.6 Amgen, Inc.

9.1.6.1 Business overview

9.1.6.2 Product and service offerings

9.1.7 Radius Health, Inc.

9.1.7.1 Business overview

9.1.7.2 Product and service offerings

9.1.8 Teva Pharmaceutical Industries Ltd.

9.1.8.1 Business overview

9.1.8.2 Product and service offerings

9.1.9 GlaxoSmithKline plc

9.1.9.1 Business overview

9.1.9.2 Product and service offerings

9.2 Strategic Developments in the Osteoporosis Drug Market

9.2.1 Merger & acquisition

9.2.2 Collaboration/ partnership

9.2.3 Product launch

9.2.4 Others

Chapter 10. Appendix

10.1 List of Abbreviations

 

LIST OF TABLES

TABLE 1: SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2: GLOBAL OSTEOPOROSIS DRUG MARKET SNAPSHOT

TABLE 3: T-SCORE TABLE

TABLE 4: HEALTHCARE EXPENDITURE AS % OF GDP

TABLE 5: SOME OF THE OSTEOPOROSIS DRUGS IN PIPELINE

TABLE 6: DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 7: RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 8: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 9: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 10: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2012 – 2015)

TABLE 11: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2016 – 2022)

TABLE 12: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2012 – 2015)

TABLE 13: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2016 – 2022)

TABLE 14: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2012 – 2015)

TABLE 15: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2016 – 2022)

TABLE 16: GLOBAL CALCITONIN MARKET, BY REGION, $M (2012 – 2015)

TABLE 17: GLOBAL CALCITONIN MARKET, BY REGION, $M (2016 – 2022)

TABLE 18: GLOBAL SERM MARKET, BY REGION, $M (2012 – 2015)

TABLE 19: GLOBAL SERM MARKET, BY REGION, $M (2016 – 2022)

TABLE 20: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2012 – 2015)

TABLE 21: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2016 – 2022)

TABLE 22: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 23: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 24: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 25: NORTH AMERICA OSTEOPOROSIS DURG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 26: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 27: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 28: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 29: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 30: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 31: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 32: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 33: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 34: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 35: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 36: PFIZER, INC. – KEY FACTS

TABLE 37: ELI LILY AND COMPANY – KEY FACTS

TABLE 38: F. HOFFMANN LA ROCHE – KEY FACTS

TABLE 39: NOVARTIS AG – KEY FACTS

TABLE 40: MERCK & CO., INC. – KEY FACTS

TABLE 41: AMGEN, INC. – KEY FACTS

TABLE 42: RADIUS HEALTH, INC. – KEY FACTS

TABLE 43: TEVA PHARMACEUTICAL INDUSTRIES LTD.– KEY FACTS

TABLE 44: GLAXOSMITHKLINE PLC– KEY FACTS

 

LIST OF FIGURES

FIG 1: RESEARCH SCOPE FOR GLOBAL OSTEOPOROSIS DRUG MARKET

FIG 2: RESEARCH METHODOLOGY FOR GLOBAL OSTEOPOROSIS DRUG MARKET

FIG 3: COMPARISON OF NORMAL BONE AND THE OSTEOPOROTIC BONE

FIG 4: PATHOGENSIS OF OSTEOPOROTIC FRACTURE

FIG 5: SOME OF THE HEALTH PROBLEMS AND MEDICAL PROCEDURES LEADING TO OSTEOPOROSIS

FIG 6: PREVENTIVE MEASURES FOR OSTEOPOROSIS IN WOMEN

FIG 7: SNAPSHOT OF OSTEOPOROSIS

FIG 8: OSTEOPOROSIS FRACTURE WORLDWIDE (1990 AND 2050)

FIG 9: ROLE OF ESTROGEN IN OSTEOPOROSIS

FIG 10: AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION

FIG 11: GLOBAL OSTEOPOROSIS DRUG MARKET, $M (2012 – 2022)

FIG 12: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 13: GLOBAL OSTEOPOROSIS DRUG MARKET SPLIT, BY DRUG TYPE (2015)

FIG 14: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2012 – 2022)

FIG 15: GLOBAL OSTEOPOROSIS DRUG MARKET SPLIT, BY REGION (2015)

FIG 16: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2012 – 2022)

FIG 17: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2012 – 2022)

FIG 18: GLOBAL CALCITONIN MARKET, BY REGION, $M (2012 – 2022)

FIG 19: GLOBAL SERM MARKET, BY REGION, $M (2012 – 2022)

FIG 20: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2012 – 2022)

FIG 21: WORLDWIDE MAJOR MARKETS FOR OSTEOPOROSIS DRUG (2022)

FIG 22: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 23: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 24: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 25: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 26: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 27: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 28: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 29: PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 30: COMPETITIVE POSITIONING OF GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry